1. FDA Fast Tracks Alpha-Emitting Radioisotope AKY-1189 for Urothelial Cancer
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to AKY-1189, an investigational therapeutic agent utilizing the alpha-emitting radioisotope actinium-225 (225Ac). This designation is specifically for the treatment of urothelial cancer, a type of cancer that begins in the urothelial cells l...